RSRene L. Suleiman

Rene L. Suleiman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rene L. Suleiman has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Establishment of quantitative RNAi-based forward genetics in Entamoeba histolytica and identification of genes required for growth

    by Akhila Bettadapur, Samuel S. Hunter, Rene L. Suleiman, Maura C. Ruyechan, Wesley Huang, Charles G. Barbieri, Hannah W. Miller, Tammie S. Y. Tam, Matthew L. Settles, Katherine S. Ralston

    While Entamoeba histolytica remains a globally important pathogen, it is dramatically understudied. The tractability of E. histolytica has historically been limited, which is largely due to challenging features of its genome. To enable forward genetics, we constructed and validated the first genome-wide E. histolytica RNAi knockdown mutant library. This library allows for Illumina deep sequencing analysis for quantitative identification of mutants that are enriched or depleted after selection. We developed a novel analysis pipeline to precisely define and quantify gene fragments. We used the library to perform the first RNAi screen in E. histolytica and identified slow growth (SG) mutants. Among genes targeted in SG mutants, many had annotated functions consistent with roles in cellular growth or metabolic pathways. Some targeted genes were annotated as hypothetical or lacked annotated domains, supporting the power of forward genetics in uncovering functional information that cannot be gleaned from databases. While the localization of neither of the proteins targeted in SG1 nor SG2 mutants could be predicted by sequence analysis, we showed experimentally that SG1 localized to the cytoplasm and cell surface, while SG2 localized to the cytoplasm. Overexpression of SG1 led to increased growth, while expression of a truncation mutant did not lead to increased growth, and thus aided in defining functional domains in this protein. Finally, in addition to establishing forward genetics, we uncovered new details of the unusual E. histolytica RNAi pathway. These studies dramatically improve the tractability of E. histolytica and open up the possibility of applying genetics to improve understanding of this important pathogen.


  • Open Access

    Trogocytosis by Entamoeba histolytica Mediates Acquisition and Display of Human Cell Membrane Proteins and Evasion of Lysis by Human Serum

    by Hannah W. Miller, Rene L. Suleiman, Katherine S. Ralston

    Entamoeba histolyticacauses amoebiasis, a potentially fatal diarrheal disease. Abscesses in organs such as the liver can occur when amoebae are able to breach the intestinal wall and travel through the bloodstream to other areas of the body. Therefore, understanding howE. histolyticaevades immune detection is of great interest. Here, we demonstrate for the first time thatE. histolyticaacquires and displays human cell membrane proteins by taking “bites” of human cell material in a process named trogocytosis (“trogo-” means “nibble”), and that this allows amoebae to survive in human serum. Display of acquired proteins through trogocytosis has been previously characterized only in mammalian immune cells. Our study suggests that this is a more general feature of trogocytosis not restricted to immune cells and broadens our knowledge of eukaryotic biology. These findings also reveal a novel strategy for immune evasion by a pathogen and may apply to the pathogenesis of other infections.


  • Open Access

    Trogocytosis by Entamoeba histolytica mediates acquisition and display of human cell membrane proteins and evasion of lysis by human serum

    by Hannah Warkentin Miller, Rene L. Suleiman, Katherine S Ralston

    Entamoeba histolytica is the protozoan parasite responsible for amoebiasis. We previously showed that E. histolytica kills human cells through a mechanism that we termed trogocytosis (trogo-: nibble), due to its resemblance to trogocytosis in other organisms. In parasites, trogocytosis is used to kill host cells. In multicellular organisms, trogocytosis is used for cell-cell interactions in the immune system, in the central nervous system, and during development. Thus, nibbling is an emerging theme in cell-cell interactions both within and between species, and it is relevant to host-pathogen interactions in many different contexts. When trogocytosis occurs between mammalian immune cells, cell membrane proteins from the nibbled cell can be acquired and displayed by the recipient cell. In this study, we tested the hypothesis that through trogocytosis of human cells, amoebae acquire and display human cell membrane proteins. Here we demonstrate for the first time that through trogocytosis, E. histolytica acquires and displays human cell membrane proteins and that this leads to protection from lysis by human serum. Protection from human serum only occurs after amoebae have undergone trogocytosis of live cells, but not phagocytosis of dead cells. Likewise, mutant amoebae that exhibit a phagocytosis defect, but are unaltered in their capacity to perform trogocytosis, are nevertheless protected from human serum. Our studies are the first to demonstrate that amoebae can display human cell membrane proteins and suggest that acquisition and display of membrane proteins is a general feature of trogocytosis that is not restricted to trogocytosis between mammalian immune cells. These studies have major implications for interactions between E. histolytica and the immune system and also reveal a novel strategy for immune evasion by a pathogen. Since other microbial eukaryotes use trogocytosis for cell killing, our findings may apply to the pathogenesis of other infections.